ALS (ALQ) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
9 Jul, 2026Opening remarks and agenda
Meeting declared open with a quorum present; directors and key executives introduced, including new board member Catharine Farrow and outgoing director Tonianne Dwyer.
Chairman outlined meeting procedures, voting process, and opportunities for shareholder questions both in-person and online.
Financial performance review
FY2025 revenue grew 16% to AUD 3 billion; underlying NPAT declined slightly to AUD 312.1 million due to FX and interest costs.
Operating margin remained robust at 19.1%; strong cash generation supported a total dividend of AUD 0.386 per share (AUD 187 million total payout).
Gross capital expenditure was AUD 165 million, with 70% directed to growth initiatives.
Leverage ratio reduced from 2.3x to 1.7x post-equity raise; AUD 372.5 million raised for expansion and future M&A.
Board and executive committee updates
Catharine Farrow appointed as independent Non-Executive Director in March 2025; up for re-election.
Tonianne Dwyer stepping down after nine years; search for her replacement underway.
John Mulcahy to retire at 2026 AGM; succession planning in progress.
Latest events from ALS
- 16% revenue growth, strong cash flow, and AUD 350m equity raise for lab expansion and growth.ALQ
H2 20258 Jul 2026 - Double-digit revenue and profit growth, raised FY26 guidance, and strong cash flow.ALQ
H1 20268 Jul 2026 - Revenue up 14%, but NPAT down 3.9% amid FX and interest headwinds; Life Sciences led growth.ALQ
H1 202528 May 2026 - Record FY26 revenue and profit growth, with FY27 targets met early and strong outlook.ALQ
H2 202618 May 2026 - Digital and AI innovation, disciplined growth, and strong M&A pipeline drive future value.ALQ
Investor Day 202516 Nov 2025 - Minerals volumes decline, but Life Sciences growth offsets, with NPAT down ~5% for H1 FY25.ALQ
Trading Update13 Jun 2025